

**Remarks**

Upon entry of this amendment, Claims 17-27 and 29-33 are pending in the present application. Claim 25 is being amended.

On page 2 of the Notice of Allowability referenced above, the Examiner presented an Examiner's Amendment. That is, the Examiner entered the following:


1. In claim 9 (page 9, lines 9-10), delete the phrase "4-[2-(3-hydroxy-4-[(3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-yl)methyl]amino)-1-piperidinyl)ethyl]-6-quinolinecarbonitrile (isomer E2);".
2. In claim 9 (page 9, line 12), delete the phrase "E1 isomer".

The Examiner characterized the amendments as typographical errors.

Applicants respectfully traverse the Examiner's Amendment. The language cited by the Examiner is not a typographical error. Rather, the last two compounds of claim 25 (renumbered by the Examiner as claim 9) correspond to different isomeric forms of 4-[2-(3-hydroxy-4-[(3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-yl)methyl]amino)-1-piperidinyl)ethyl]-6-quinolinecarbonitrile, in particular corresponding to the compounds prepared in Example 11 (isomer E2) and Example 13 (E1 Isomer).

The present amendment reinstates the original language prior to the Examiner's Amendment. Applicants respectfully request entry of this amendment.

Respectfully submitted,

  
Loretta J. Sauermelch  
Attorney for Applicants  
Registration No. 37,347

GLAXOSMITHKLINE  
Corporate Intellectual Property – UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Tel: 610 270 6854  
Fax: 610 270 5090  
N:\Loretta\Applications\IP3's\IP33071\312 amend.doc